Product Description
Mechanisms of Action: HSP90 Inhibitor, ALK Inhibitor, EGFR Inhibitor, IGF Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Intravenous
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Novartis
Company Location: Europe
Company CEO: Vasant Narasimhan
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Multiple Myeloma|Gastrointestinal Cancer|Non-Small-Cell Lung Cancer|Small Cell Lung Cancer|Gastrointestinal Stromal Tumors|Breast Cancer|Pancreatic Cancer|Lymphoma|Myelofibrosis|Adenocarcinoma|Myeloproliferative Disorders|Esophageal Cancer|Thrombocytosis|Thrombocythemia, Essential|Polycythemia Vera|Prostate Cancer
Phase 1: Gastrointestinal Cancer|Esophageal Cancer|Squamous Cell Carcinoma|Non-Small-Cell Lung Cancer|Lymphoma|Oncology Solid Tumor Unspecified|Colorectal Cancer|Malaria|Adenocarcinoma
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
ACTRN12620000995976p |
18-1100.cc | P1 |
Not yet recruiting |
Malaria |
2022-03-26 |
|||
NCT01784640 |
NCI-2013-00410 | P1 |
Completed |
Squamous Cell Carcinoma|Non-Small-Cell Lung Cancer |
2018-10-11 |
27% |
2019-04-24 |
Primary Completion Date|Study Completion Date|Treatments|Trial Status |
NCT01772797 |
CLDK378X2102 | P1 |
Completed |
Lymphoma|Non-Small-Cell Lung Cancer |
2016-01-01 |
2019-03-19 |
Treatments |
|
NCT01294826 |
CAUY922AUS06T | P1 |
Completed |
Adenocarcinoma|Colorectal Cancer |
2015-05-01 |
2019-03-19 |
Treatments |
|
JapicCTI-132296 |
JapicCTI-132296 | P1 |
Terminated |
Gastrointestinal Cancer |
2014-07-01 |
|||
NCT01613950 |
CBYL719X2103 | P1 |
Completed |
Gastrointestinal Cancer|Esophageal Cancer |
2014-03-01 |
2019-03-19 |
Treatments |
|
2011-002570-23 |
2011-002570-23 | P2 |
Terminated |
Gastrointestinal Cancer |
2029-12-22 |
2022-03-13 |
Treatments |
|
CTR20140725 |
CTR20140725 | P2 |
Completed |
Adenocarcinoma |
2019-10-15 |
2025-04-29 |
||
NCT01752400 |
NCT01752400 | P2 |
Completed |
Non-Small-Cell Lung Cancer |
2017-06-01 |
2019-03-19 |
Treatments |
|
NCT01854034 |
NCT01854034 | P2 |
Completed |
Non-Small-Cell Lung Cancer |
2017-03-01 |
2019-03-19 |
Treatments |
|
NCT01922583 |
NSCLC | P2 |
Completed |
Non-Small-Cell Lung Cancer |
2017-02-01 |
2019-03-19 |
Treatments |
|
ACTRN12614000789662 |
ACTRN12614000789662 | P2 |
Not yet recruiting |
Prostate Cancer |
2016-09-19 |
2024-08-29 |
Treatments |
|
2011-005655-13 |
TRY | P2 |
Completed |
Non-Small-Cell Lung Cancer |
2016-06-09 |
2022-03-13 |
Treatments |
|
NCT01646125 |
CAUY922A2207 | P2 |
Terminated |
Non-Small-Cell Lung Cancer |
2015-11-04 |
2019-08-10 |
Patient Enrollment|Primary Completion Date|Primary Endpoints|Start Date|Study Completion Date|Treatments |
|
NCT01485536 |
NCI-2012-00070 | P2 |
Terminated |
Lymphoma |
2015-11-01 |
2019-03-19 |
Treatments |
|
NCT01389583 |
T2211 | P2 |
Unknown status |
Gastrointestinal Stromal Tumors |
2015-05-01 |
2019-10-03 |
Primary Endpoints|Treatments|Trial Status |
|
NCT01668173 |
NCT01668173 | P2 |
Terminated |
Myelofibrosis|Myeloproliferative Disorders|Thrombocytosis|Polycythemia Vera|Thrombocythemia, Essential |
2015-05-01 |
2019-03-19 |
Treatments |
|
2012-001050-25 |
2012-001050-25 | P2 |
Completed |
Non-Small-Cell Lung Cancer|Small Cell Lung Cancer |
2015-04-05 |
2022-03-13 |
Treatments |
|
NCT01404650 |
SCRI GI 148 | P2 |
Completed |
Gastrointestinal Stromal Tumors |
2015-02-01 |
2019-03-19 |
Treatments |
|
NCT01124864 |
CAUY922A2206 | P2 |
Completed |
Non-Small-Cell Lung Cancer |
2014-08-01 |
2019-03-19 |
Treatments |
|
NCT01271920 |
CAUY922A2109 | P2 |
Completed |
Breast Cancer |
2013-10-01 |
2020-09-09 |
||
2009-015628-27 |
2009-015628-27 | P2 |
Completed |
Breast Cancer |
2013-09-11 |
2022-03-13 |
Treatments |
|
NCT01484860 |
DDP-922 | P2 |
Terminated |
Adenocarcinoma|Pancreatic Cancer |
2013-08-01 |
2019-03-19 |
Treatments |
|
JapicCTI-111669 |
JapicCTI-111669 | P2 |
Completed |
Gastrointestinal Cancer |
2013-07-01 |
|||
NCT01259089 |
NU 10L01 | P2 |
Completed |
Non-Small-Cell Lung Cancer|Adenocarcinoma |
2013-06-04 |
2019-09-12 |